Literature DB >> 29059152

MiR-22 sustains NLRP3 expression and attenuates H. pylori-induced gastric carcinogenesis.

S Li1, X Liang1, L Ma1, L Shen1, T Li1, L Zheng1, A Sun1, W Shang1, C Chen2, W Zhao3, J Jia1.   

Abstract

Chronic inflammation is the primary cause of gastric cancer (GC). NLRP3, as an important inflammasome component, has crucial roles in initiating inflammation. However, the potential roles of NLRP3 in GC is unknown. Here, we show that NLRP3 expression is markedly upregulated in GC, which promotes NLRP3 inflammasome activation and interleukin-1β (IL-1β) secretion in macrophages. In addition, NLRP3 binds to cyclin-D1 (CCND1) promoter and promotes its transcription in gastric epithelial cells. Consequently, NLRP3 enhances epithelial cells proliferation and GC tumorigenesis. Furthermore, we identify miR-22, which is constitutively expressed in gastric mucosa, as a suppressor of NLRP3. MiR-22 directly targets NLRP3 and attenuates its oncogenic effects in vitro and in vivo. However, Helicobacter pylori (H. pylori) infection suppresses miR-22 expression, while enhances NLRP3 expression, and that triggers uncontrolled proliferation of epithelial cells and the emergence of GC. Thus, our research describes a mechanism by which miR-22 suppresses NLRP3 and maintains homeostasis of gastric microenvironments and suggests miR-22 as a potential target for the intervention of GC.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29059152     DOI: 10.1038/onc.2017.381

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  53 in total

Review 1.  Inflammasomes in health and disease.

Authors:  Till Strowig; Jorge Henao-Mejia; Eran Elinav; Richard Flavell
Journal:  Nature       Date:  2012-01-18       Impact factor: 49.962

2.  Aryl hydrocarbon receptor negatively regulates NLRP3 inflammasome activity by inhibiting NLRP3 transcription.

Authors:  Wanwan Huai; Rui Zhao; Hui Song; Jing Zhao; Lei Zhang; Lining Zhang; Chengjiang Gao; Lihui Han; Wei Zhao
Journal:  Nat Commun       Date:  2014-08-20       Impact factor: 14.919

3.  Modification of Helicobacter pylori Peptidoglycan Enhances NOD1 Activation and Promotes Cancer of the Stomach.

Authors:  Giovanni Suarez; Judith Romero-Gallo; M Blanca Piazuelo; Ge Wang; Robert J Maier; Lennart S Forsberg; Parastoo Azadi; Martin A Gomez; Pelayo Correa; Richard M Peek
Journal:  Cancer Res       Date:  2015-03-02       Impact factor: 12.701

4.  The receptor NLRP3 is a transcriptional regulator of TH2 differentiation.

Authors:  Mélanie Bruchard; Cédric Rebé; Valentin Derangère; Dieudonnée Togbé; Bernhard Ryffel; Romain Boidot; Etienne Humblin; Arlette Hamman; Fanny Chalmin; Hélène Berger; Angélique Chevriaux; Emeric Limagne; Lionel Apetoh; Frédérique Végran; François Ghiringhelli
Journal:  Nat Immunol       Date:  2015-06-22       Impact factor: 25.606

5.  Gastric cancer.

Authors:  Henk H Hartgrink; Edwin P M Jansen; Nicole C T van Grieken; Cornelis J H van de Velde
Journal:  Lancet       Date:  2009-07-20       Impact factor: 79.321

6.  Helicobacter pylori-induced IL-1β secretion in innate immune cells is regulated by the NLRP3 inflammasome and requires the cag pathogenicity island.

Authors:  Raphaela P Semper; Raquel Mejías-Luque; Christina Groß; Florian Anderl; Anne Müller; Michael Vieth; Dirk H Busch; Clarissa Prazeres da Costa; Jürgen Ruland; Olaf Groß; Markus Gerhard
Journal:  J Immunol       Date:  2014-08-29       Impact factor: 5.422

7.  Deregulation of the NLRP3 inflammasome in hepatic parenchymal cells during liver cancer progression.

Authors:  Qing Wei; Kun Mu; Tao Li; Ying Zhang; Zhaowen Yang; Xiaoqing Jia; Wei Zhao; Wanwan Huai; Pengbo Guo; Lihui Han
Journal:  Lab Invest       Date:  2013-10-28       Impact factor: 5.662

8.  miR-22 represses cancer progression by inducing cellular senescence.

Authors:  Dan Xu; Fumitaka Takeshita; Yumiko Hino; Saori Fukunaga; Yasusei Kudo; Aya Tamaki; Junko Matsunaga; Ryou-U Takahashi; Takashi Takata; Akira Shimamoto; Takahiro Ochiya; Hidetoshi Tahara
Journal:  J Cell Biol       Date:  2011-04-18       Impact factor: 10.539

9.  The E3 ubiquitin ligase TRIM31 attenuates NLRP3 inflammasome activation by promoting proteasomal degradation of NLRP3.

Authors:  Hui Song; Bingyu Liu; Wanwan Huai; Zhongxia Yu; Wenwen Wang; Jing Zhao; Lihui Han; Guosheng Jiang; Lining Zhang; Chengjiang Gao; Wei Zhao
Journal:  Nat Commun       Date:  2016-12-08       Impact factor: 14.919

10.  NLRC3 is an inhibitory sensor of PI3K-mTOR pathways in cancer.

Authors:  Rajendra Karki; Si Ming Man; R K Subbarao Malireddi; Sannula Kesavardhana; Qifan Zhu; Amanda R Burton; Bhesh Raj Sharma; Xiaopeng Qi; Stephane Pelletier; Peter Vogel; Philip Rosenstiel; Thirumala-Devi Kanneganti
Journal:  Nature       Date:  2016-12-12       Impact factor: 49.962

View more
  35 in total

1.  The platelet NLRP3 inflammasome is upregulated in a murine model of pancreatic cancer and promotes platelet aggregation and tumor growth.

Authors:  Brian A Boone; Pranav Murthy; Jennifer L Miller-Ocuin; Xiaoyan Liang; Kira L Russell; Patricia Loughran; Meinrad Gawaz; Michael T Lotze; Herbert J Zeh; Sebastian Vogel
Journal:  Ann Hematol       Date:  2019-04-24       Impact factor: 3.673

2.  Wnt/beta-catenin signaling confers ferroptosis resistance by targeting GPX4 in gastric cancer.

Authors:  Jiping Zeng; Jihui Jia; Yue Wang; Lixin Zheng; Wenjing Shang; Zongcheng Yang; Tongyu Li; Fen Liu; Wei Shao; Lin Lv; Li Chai; Lingxin Qu; Qing Xu; Jie Du; Xiuming Liang
Journal:  Cell Death Differ       Date:  2022-05-09       Impact factor: 15.828

Review 3.  Chronic inflammation and long-lasting changes in the gastric mucosa after Helicobacter pylori infection involved in gastric cancer.

Authors:  Hang Yang; Bin Wei; Bing Hu
Journal:  Inflamm Res       Date:  2021-09-21       Impact factor: 4.575

4.  Downstream Signaling of Inflammasome Pathway Affects Patients' Outcome in the Context of Distinct Molecular Breast Cancer Subtypes.

Authors:  Concetta Saponaro; Annarita Fanizzi; Margherita Sonnessa; Paolo Mondelli; Daniele Vergara; Donato Loisi; Raffaella Massafra; Agnese Latorre; Francesco A Zito; Laura Schirosi
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-24

Review 5.  Update on molecular biomarkers for diagnosis and prediction of prognosis and treatment responses in gastric cancer.

Authors:  Masahiro Sasahara; Mitsuro Kanda; Yasuhiro Kodera
Journal:  Histol Histopathol       Date:  2021-03-09       Impact factor: 2.303

Review 6.  Clinical crosstalk between microRNAs and gastric cancer (Review).

Authors:  Jing Ouyang; Zhizhong Xie; Xiaoyong Lei; Guotao Tang; Runliang Gan; Xiaoyan Yang
Journal:  Int J Oncol       Date:  2021-03-02       Impact factor: 5.650

7.  MicroRNA-22 represses glioma development via activation of macrophage-mediated innate and adaptive immune responses.

Authors:  Jiajie Tu; Yilong Fang; Dafei Han; Xuewen Tan; Zhen Xu; Haifeng Jiang; Xinming Wang; Wenming Hong; Wei Wei
Journal:  Oncogene       Date:  2022-03-12       Impact factor: 9.867

Review 8.  Targeting the NLRP3 Inflammasome as a New Therapeutic Option for Overcoming Cancer.

Authors:  Sonia Missiroli; Mariasole Perrone; Caterina Boncompagni; Chiara Borghi; Alberto Campagnaro; Francesco Marchetti; Gabriele Anania; Pantaleo Greco; Francesco Fiorica; Paolo Pinton; Carlotta Giorgi
Journal:  Cancers (Basel)       Date:  2021-05-11       Impact factor: 6.639

Review 9.  NLRP3 Inflammasome Activation in Cancer: A Double-Edged Sword.

Authors:  Shaima'a Hamarsheh; Robert Zeiser
Journal:  Front Immunol       Date:  2020-07-08       Impact factor: 7.561

10.  NLRP3 Inflammasome Promotes the Progression of Acute Myeloid Leukemia via IL-1β Pathway.

Authors:  Chaoqin Zhong; Ruiqing Wang; Mingqiang Hua; Chen Zhang; Fengjiao Han; Miao Xu; Xinyu Yang; Guosheng Li; Xiang Hu; Tao Sun; Chunyan Ji; Daoxin Ma
Journal:  Front Immunol       Date:  2021-06-15       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.